Kaleidas’ Kathleen Giuliani tells FemTech World how the community-based platform is aiming to improve menstrual care and break down taboos
“Kaleidas comes from kaleidoscope,” Kathleen Giuliani tells me at the start of our interview. “A kaleidoscope allows anyone who looks into it to have their own vision and this is what we aim to do as well.”
Kaleidas is a community-based platform and a branch of electronRx, a Cambridge-based biotech company, aiming to tackle some of the biggest challenges in healthcare.
Giuliani works on the business development and brand design department and she tells me that after doing some market research, they found out that there was a huge demand in expanding the conversation around menstruation and women’s health.
“In a really short term, we had lots of followers on Instagram, just talking about dysmenorrhea and being interested in finding out more about menstrual health. Our community grew enormously in the beginning and we noticed that there is interest and there is a need.
“So, we wanted to create a forum-based platform where we want to inform women and menstruators on how their body works, so that they can be empowered by knowledge and communicate to their doctors in an effective way.”
Inclusivity was a very important aspect in achieving this, says Giuliani. “When I was building the design, I saw that pink would come up every time I looked at any type of branding regarding menstrual health.
“And I think it’s a very limiting colour, regarding inclusivity and we clearly didn’t want that. So, all the different colours we used in our logo suggest that you can see your reality through our kaleidoscope without having the need to conform to a certain vision.
“I think these small steps do make a difference,” she continues. “The language is another important aspect. If we start using specific words, it’s because the community has approved them. The word ‘menstruators’ is working and it came out from our survey. People are happy to be called menstruators.”
Stigma around menstruation still affects thousands of women. A YouGov poll has shown that more than one in three women in the UK have experienced period shaming. “We need to disrupt the system somehow and break down the stigma around menstruation,” Giuliani says.
“Every time we talk about Kaleidas and our project, it’s empowering to see the reaction of people, not just female, but also male. It’s still a challenge to make everyone understand the importance of talking about menstrual health. It was a taboo subject for a very long time, but I think if we start talking about it, half of the job is done.”
Kaleidas aims not just to connect but also to inform and educate people abut menstrual health. Giuliani believes that: “It’s all about rewriting the history, reframing what menstrual health is and understanding the importance of having a healthy menstrual life so that we can empower ourselves. We have this incredible machine working in us and I think that change in perception has to start from us.”
With the help of a grant from Innovate UK, the team behind Kaleidas is also developing a wearable, period pain relief device called Ohmm.
“Ohmm is essentially a medically approved device that helps women and menstruators to deal with dysmenorrhea,” Giuliani explains. “The grant from Innovate UK was very important because it shows that our product is needed in the market so much that the government is financing us.
“It made us really proud and it will allow us to go in the right direction and to bring people and high technology together. I’m hoping that our community keeps growing and that everyone can work hand in hand with us to develop better high tech solutions for the future.”
To find out more information, visit kaleidas.com.
Researchers to develop portable hormone monitoring device
The device is hoped to help women identify symptoms that could be signs of common female health conditions
Scientists from Edinburgh’s Heriot-Watt University are working on a new portable device that could help women track and monitor their health and hormones.
The gadget will be smaller than an iPhone and will keep track of the full picture of women’s health, from period symptoms to hormone fluctuations, mood and sleep.
The device is hoped to help women identify symptoms that could be signs of common health conditions, such as polycystic ovary syndrome (PCOS), and alert them when they would need to see a doctor.
The researchers hope it will capture data on a variety of fertility-related hormones, like luteinising hormone, which stimulates ovulation, and others like thyroid-stimulating hormone.
The project, led by Dr Sadeque Reza Khan, a specialist in biomedical devices and sensing in Heriot-Watt’s Institute of Sensors, Signals and Systems, is funded by the Scottish Government.
Improving women’s healthcare
According to the Royal College of Obstetricians and Gynaecologists (RCOG), the waiting list for gynaecology appointments, diagnosis and treatment has soared up to 60 per cent recently, affecting more than half a million female patients.
A study conducted by the RCOG in 2022 shows such delays can significantly affect women’s physical and mental health, as well as their quality of life.
“We’re working on building a device that will be about half the size of an iPhone and completely portable. Women will be able to take it everywhere,” explained Dr Khan.
“Women will be able to test both blood and urine, as well as record symptoms, which will provide the most accurate and real-time picture of their health. The device will transfer key data wirelessly to an app, and share it with a gynaecologist.
“At Heriot-Watt we are working on the hardware development and miniaturisation aspect of the device, which is critical as we envision a portable female health monitoring device which women can carry anywhere and reliably use without any hassle.”
Dr Khan is working with viO HealthTech, whose OvuSense device provides continuous general monitoring of the reproductive cycle, and Dr Ruchi Gupta from the University of Birmingham, an expert in developing biosensors.
Rob Milnes, CEO of viO HealthTech, said: “Our users tell us they want access to personalised health information and insights that can help them make informed decisions about their health not only when issues occur, but to avoid those issues in the first place.
“This project offers the exciting prospect of targeted diagnostics added to our existing monitoring system”
Dr Ruchi Gupta from the University of Birmingham, added: “We have been developing our leaky waveguide (LW) biosensor to measure different types of biomarkers; proteins, DNA, hormones, and even cells.
“Our LW biosensor will be at the heart of the gadget for women’s health monitoring. Our partnership with Dr Khan and viO HealthTech will be a key step in the translation of our LW biosensor from bench to bedside. ”
Concept to commercialisation
The team have already started working on the project and, once they have proof of concept, they want to start focusing on making the device commercially available.
“As well as making sure we meet all regulatory requirements, we need to ensure that women can afford the device,” said Khan.
“We’re focused on making sure we are using affordable, sustainable materials that will make this available to a greater number of women.”
Professor Steve McLaughlin, deputy principal of research and impact at Heriot-Watt University, said: “The development of this device demonstrates how our new centre of excellence will support the creation of ground-breaking technologies that have the potential to revolutionise patient care.
“Bringing together academics and industry experts, we want to accelerate the process of bringing these vital developments to market.
“We already have several research projects underway and the next 12 months are going to be a really exciting time as we showcase our developments on the global stage.”
Canadian period pain relief company makes first acquisition
The acquisition is hoped to help Somedays improve the range of period care products available on the market
The Canadian period pain relief company Somedays has acquired the period care brand Aisle in an effort to “redefine” the future of menstrual care.
Lux Perry, founder and CEO of Somedays, has said the acquisition of Aisle would help the company prioritise reproductive health and improve the range of period care products available on the market.
“The philosophy underpinning this acquisition prioritises keeping reproductive health businesses in the hands of those they serve and celebrating an impact-based brand that has been at the forefront of the menstrual health movement for decades,” Perry said.
“It may sound idealistic, but I believe that good business and good values are not mutually exclusive. The strategic aspect of the deal lies in the synergy of the two company’s shared audiences and complementary product lines.”
Suzanne Siemens, co-founder of Aisle, said: “Aisle’s story is deeply rooted in menstrual equity and advocacy.
“As we pass the torch to Lux, we are confident that the vision of universal, sustainable access to menstrual care we’ve championed will continue to flourish for generations to come.”
Aisle co-founder, Madeleine Shaw, added: “This intergenerational union exemplifies a fusion of experience and new energy, breathing fresh life into Aisle’s foundational values of sustainability, transparency and body autonomy that have guided the brand for over three decades.”
Founded by a group of friends with period pain and endometriosis who needed better pain relief options, Vancouver-based Somedays is developing plastic-free products for period pain relief.
“Somedays is my retaliation for the 20 years I spent being invalidated, dismissed and ignored by a society that told me my pain was normal,” explained Perry.
“I had my first experience with debilitating period pain when I was hospitalised for it at nine years old. For the next 20 years, I was passed from physician to physician, trying to find answers and relief.
“I spent a decade on birth control and countless additional medications to combat the side effects of that. None of it worked. I was finally diagnosed with endometriosis in 2021.”
The company, famous for its viral period pain simulator videos with over three billion views, aims to bring a bold vision for the future of menstrual wellness and expand into menstrual healthcare services.
According to Perry, the acquisition of Aisle has the potential to propel the two companies into an exciting future where innovation and product development take centre stage.
“We envision a revolutionary approach to health that will boldly shape the future of menstrual care,” the founder said.
Virtual care platform raises US$10m to support women with common gynaecological conditions
Gynaecological health is one of the least prioritised areas of health globally, despite an enormous burden of morbidity and mortality
The US virtual care platform Allara has raised US$10m in Series A funding to support women with common hormonal and gynaecological conditions.
Allara is a specialty care platform for women living with complex hormonal and gynaecological conditions, such as polycystic ovary syndrome (PCOS) and endometriosis.
The company aims to pair patients with specially trained doctors and dietitians to fill, what it describes as, a significant gap in women’s healthcare.
Globally, gynaecological health is one of the least prioritised areas of health, despite an enormous burden of morbidity and mortality.
Research shows over one in three women live with a chronic condition, such as polycystic ovary syndrome (PCOS), endometriosis, or hypothyroidism.
Despite this, women report years of suffering and go as many as 10 years undiagnosed. These conditions often cause complications such as infertility, high-risk pregnancies, obesity, and diabetes, as well as delayed diagnoses and treatments.
“Women’s health is often misperceived as limited to pregnancy and fertility, failing to acknowledge the intricate web of health conditions that affect women’s daily lives and long-term health,” said Rachel Blank, who founded Allara after her own difficulty navigating a PCOS diagnosis without sufficient medical support.
“At Allara, we finally take the burden off the patient to navigate a siloed care system and empower her with a whole-body, preventative approach to her health.”
The company’s latest round was led by Google Ventures, with participation from Great Oaks Venture Capital, Humbition, Vanterra, Gaingels, and individual investors, including Tom Lee (One Medical) and Maggie Sellers.
The start-up will use the new funds to expand access to care by extending its insurance coverage, launching partnerships with health systems and conducting clinical research.
Blank said: “We are grateful for the support of GV and our dedicated partners to scale our operations and extend this vital care offering to women nationwide.”
Frédérique Dame, GV general partner, added: “Women of reproductive age have complex hormonal care needs, and Allara raises the bar for clinically driven, personalised hormonal healthcare.
“Allara has built a brand and community that hundreds of thousands of patients trust, and we’re excited to support CEO Rachel Blank and the team as they provide women with compassionate, modern healthcare.”
- Lawyers warn of discrimination risks around lack of menstrual health support in the workplace
- OB/GYN-founded vitamin company pledges US$10m to improve women’s health research
- New treatment could ‘disrupt’ growth of breast cancer tumours
- The slippery slope of presumed consent in post-humous reproductive health cases
- Women’s health content censored and blocked on social media
Receive updates from Femtech World
- Femtech World Awards4 weeks ago
Ground-breaking research to be celebrated at Femtech World Awards
- News2 weeks ago
Start-up secures Series A funding round for wearable urinary incontinence device
- News3 weeks ago
Partnership to pilot ‘cutting-edge’ embryo selection tool
- News1 week ago
Irish clinic launches menopause app to help researchers develop new treatments
- News2 weeks ago
Start-up raises US$1.7m to tackle breast cancer in women with dense tissue
- News2 days ago
US fertility clinic network raises US$20m to ‘democratise’ IVF
- News4 weeks ago
McKinsey report underscores US$1tn potential of closing gender health gap
- News2 weeks ago
‘No more cute mentorship programmes’: femtech community reacts to Women’s Health Strategy